Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN, INC.
05/23 Lundin Law PC Announces an Investigation of Amgen Inc. and Advises Investors ..
05/23 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amgen Inc. (AMG..
05/23 NEUROPACE : Develops and markets implantable devices for the treatment of neurol..
05/23 AMGEN, INC. : Blog Coverage: Amgen Announces New Data from the FOURIER Trial
05/23 AMGEN : shares fall as it reveals new cardiovascular risks for its Evenity osteo..
05/22 Goldberg Law PC Announces an Investigation of Amgen Inc.
05/22 AMGEN INC : Change in Directors or Principal Officers, Submission of Matters to ..
05/22 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. -..
05/22 AMGEN : Health and Human Services Department (HHS); Food and Drug Administration..
05/22 AMGEN, INC. (NASDAQ : AMGN) Osteoporosis Drug Fails Following Heart Safety Risk ..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/22 More Break Than Make For Amgen As Romo Trips Over Safety
05/22 BIOTECH FORUM DAILY DIGEST : Analysts Warming To Mylan; Spotlight On Seres Thera..
05/22 My 83 Stock Portfolio Requirements And Listing Of Do Not Sell, Core And Specu..
05/22 Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but..
05/22 Healthcare Dogs See Psychemedics Tops By Gains In May
Financials ($)
Sales 2017 22 648 M
EBIT 2017 11 765 M
Net income 2017 8 141 M
Finance 2017 1 074 M
Yield 2017 2,96%
P/E ratio 2017 13,87
P/E ratio 2018 13,72
EV / Sales 2017 4,92x
EV / Sales 2018 4,33x
Capitalization 112 531 M
More Financials
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 183 $
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.4.66%112 531
GILEAD SCIENCES, INC.-10.12%84 101
ACTELION LTD24.04%30 824
More Results